KPRX vs THH Comparison

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.